Deutsche Bank Maintains Buy Rating, $28 PT On AUXL

Deutsche Bank is tweaking its Auxilium Pharmaceuticals, Inc. AUXL 2011 revenue estimate from $268M to $269M but lowering its 2011 EPS estimate from $(0.56) to $(0.83), primarily on higher R&D and lower gross margins. “We are also modestly lowering our 2012-14 revenue and EPS estimates, primarily on slightly lower Testim sales,” Deutsche Bank writes. “With a current market cap of $1.14B, the implied value for Xiaflex is approx $384M (ex-cash of $128M and applying a 3x rev multiple to our 2011 Testim est of $208M). “We view this as increasingly attractive, given its potential applicability in a number of other unmet medical needs (e.g., Peyronies, cellulite, etc.). “Rolling forward our valuation metrics, our 12-month PT remains $28, based on 24x our fully taxed 2013 EPS est of $1.33 (previously $1.57), discounted back 1 year at 15%. Key risks to our target include potential regulatory, reimbursement, or commercial setbacks for Xiaflex, as well as potential changes in the Testim growth outlook.” Auxilium Pharmaceuticals closed Thursday at $22.24.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst RatingsAuxilium PharmaceuticalsDeutsche BankHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!